Ophthalmic Drugs Conference 2017

SMi Group28 - 29 November 2017, London, UK.
Ophthalmic Drugs Conference 2017 will gather industry leaders to discuss the latest challenges and changes in the field of ophthalmology. Explore novel approaches to treatment, ocular medical devices, targeted drug delivery technology and real-life challenges to pre-clinical and clinical trials, to deepen your understanding of inherited ocular diseases.

Ocular disease therapy has seen a surge in innovation in areas ranging from glaucoma to macular degeneration and diabetic retinopathy. As ageing populations grow globally the need for treatment in this field has grown and is expected to reach a figure of $21 billion by the year 2022.

How Will You Benefit?

Network and learn from leading professionals such as:
  • Naj Sharif, Executive Director in R&D, Head, Global Alliances & External Research, Santen Inc
  • Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals
  • Michael Lai, Global Program Medical Director, Novartis
  • Sérgio Leal, Ophthalmologist Director, Global Clinical Leader, Bayer
  • Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim
  • Amir Shojaei, Vice President Therapeutic Area Head, Ophthalmology, Shire
  • Tomas Navratil, Senior Vice President, Development, Envisia Therapeutics
Visit the website for the full speaker line-up here

Some of the featured highlights will include:

  • New approaches to drug delivery to the back of the eye and nanotechnology
  • Discover innovation in diagnostic technology
  • Regulatory keynote on medical devices and human factors
  • Explore various combination products improving health outcomes
Exciting insight into stem cell and gene therapy

For further information and to register, please visit:
http://www.smi-online.co.uk/pharmaceuticals/uk/Opthalmic-Drugs

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...